Journal
INTERNATIONAL JOURNAL OF PHARMACEUTICS
Volume 445, Issue 1-2, Pages 79-87Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ijpharm.2013.01.057
Keywords
Malignant glioma; Apoptosis; Gene delivery; PAMAM-R; Interferon beta
Categories
Funding
- Gene Therapy Project of the Ministry of Education, Science and Technology in the Republic of Korea [200110018684]
- Basic Science Research Program through a National Research Foundation of Korea (NRF)
- Korean government [2001K000818]
Ask authors/readers for more resources
xenograft brain tumor model was established by the subcutaneous injection of U87MG cells into nude mice to investigate the efficacy of a non-viral vector, arginine-modified polyamidoamine dendrimer (PAMAM-R), in delivering a therapeutic gene, human interferon beta (IFN-beta). We used 4 ',6-diamidino-2- phenylindole staining, the terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay, and the caspase-3 activity assay to determine the induction of apoptosis upon transfection with the PAMAM-R/IFN-beta gene polyplex in vitro. The polyplex was injected into xenograft brain tumors. Mice treated with PAMAM-R/pORF-IFN-beta exhibited a significantly smaller tumor size than control mice and PAMAM-R/pORF treated mice. Hematoxylin/eosin staining and immunohistochemistry with the endothelial growth factor receptor antibody also revealed inhibition of tumor growth. Furthermore, reverse transcription polymerase chain reaction and the TUNEL assay also verified the expression of IFN-beta and induction of apoptosis in vivo. These results indicate that the PAMAM-R/pORF-IFN-beta polyplex is an effective therapeutic candidate for glioblastoma multiforme due to its selective induction of apoptosis in tumor cells. (C) 2013 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available